The Lancet Oncology · 2019 · 477 citations · 17 references
MedicineOncologyPharmacologyBreast OncologyCancer PharmacologyImmunotherapyBreast Cancer PharmacotherapyCancer ImmunotherapyHer2-positive Breast CancerImmunotherapy For Breast CancerMetastatic Breast CancerPharmacodynamics Of ImmunotherapiesHer2-positive Breast Cancer ImmunotherapyHer2-positive Breast Cancer TherapyHormone Receptor-positive Breast Cancer TherapyPembrolizumab TherapyTrastuzumab Resistance
17
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2015 · 8.1K citations · Full text
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.2K citations · Full text
Medicine, Oncology, Pharmacology +17
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Omid Hamid, Caroline Robert, Adil Daud et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text
Medicine, Immunology, Oncology +17
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Raphael Clynes, Terri L. Towers, Leonard G. Presta et al. · Nature Medicine · 2000 · 2.7K citations
Medicine, Cancer Biology, Oncology +15